Volume 15, Issue 58 (7-2006)                   jour guilan uni med sci 2006, 15(58): 7-14 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Silanian Toosi M, Salehi M, Saidi Saedi H. Clinical Evaluation of Serum CEA and CA15-3 in Patients with Breast Cancer. jour guilan uni med sci. 2006; 15 (58) :7-14
URL: http://journal.gums.ac.ir/article-1-458-en.html
Abstract:   (54012 Views)
Abstract Introduction: Tumor markers are useful means for obtaining information about some malignant tumors whilst causing minimal inconvenience and cost. Objective: The purpose of this study was to evaluate the value of CA 15-3 and CEA in patients with breast carcinoma. Materials and Methods: This retrospective study was performed on 604 patients (mean age= 47 years) who were referred for treatment to oncology departments of Ghaem and Omid hospitals of (Mashhad Iran) from 1999 to 2004. CEA (cut off, 5 ng/ml) and CA 15-3 (cut off, 40 U/ml) had been measured with radioimmunoassay method for every patient (1- 10 times). Results: Stage I to IV were found in 25, 370, 165 and 44 patients respectively at the time of referral. With a mean follow up time of 18 months, from 560 nonmetastatic patients, 76 (13.6%) cases experienced recurrence. The sensitivity of CEA and CA 15-3 measurements in patients with overt metastasis or up to one month before the detection of recurrence were 56.4% and 90% respectively. CEA and CA 15-3 were measured 2 to 8 months before the detection of metastasis in 44 patients from which raising the levels of these markers were found in 7 (15.9%) and 23 (52.2%) cases respectively. Among 249 disease free patients who had been followed for more than 18 months, false positive levels of CEA and CA15-3 were found in 7 (2.8%) and 4 (1.7%) cases respectively. Conclusion: Considering the low number of false positive results in recurrent free patients, both CEA and CA15-3 showed good specificity. The sensitivity of CA15-3 is good for the detection of overt metastasis. However CA15-3 has a modest sensitivity in patients with minimal disease. CEA has a much lower sensitivity compared to CA15-3. However, the positive test can confirm the result of CA15-3 in metastatic setting.
Full-Text [PDF 168 kb]   (2054 Downloads)    
Type of Study: Research | Subject: Special
Received: 2014/01/14 | Accepted: 2014/01/14 | Published: 2014/01/14

Add your comments about this article : Your username or Email:

Send email to the article author

© 2019 All Rights Reserved | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb